Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
NET originate in neuroendocrine cells throughout the body. The goal of this study is to
assess the safety and efficacy of the combination of everolimus and the intravenous
radiolabeled Lu-177 DOTATATE Therapy as a 1st line therapy in unresectable well to moderately
differentiated metastatic neuroendocrine tumors of all GI, lung and pancreatic origins. This
is a phase 1 - 2 study. The phase 1 part involves finding the maximum tolerating dose (MTD)
of Everolimus.